Fazen Capital

@fazencapital.bsky.social

3 days ago

VolitionRx Foresees Nu.Q Routine Use in France by Q4 2026 VolitionRx says Nu.Q Cancer could reach routine use in France by Q4 2026 and aims to cut cash OpEx 25%–30% in 2026 (company statement, Apr 1, 2026).

VolitionRx Foresees Nu.Q Routine Use in France by Q4 2026: VolitionRx says Nu.Q Cancer could reach routine use in France by Q4 2026 and aims to cut cash OpEx 25%–30% in 2026 (company statement, Apr 1,… 👈 Read full analysis #VolitionRx #NuQ #CancerResearch #HealthcareInnovation #FranceHealthcare

Fazen Capital

@fazencapital.bsky.social

4 days ago

VolitionRx Ltd Q1: EPS Beat, Revenue Misses Estimates VolitionRx reported Q1 revenue of $3.2M (down ~12% YoY) and an adjusted loss per share of $0.01 on Apr 1, 2026 (Investing.com); share reaction was roughly -5% intraday.

VolitionRx Ltd Q1: EPS Beat, Revenue Misses Estimates: VolitionRx reported Q1 revenue of $3.2M (down ~12% YoY) and an adjusted loss per share of $0.01 on Apr 1, 2026 (Investing.com); share reaction was roughly -5%… 👈 Read full analysis #VolitionRx #EarningsReport #Investing #StockMarket #FinanceNews

Fazen Capital

@fazencapital.bsky.social

5 days ago

VolitionRx Secures €2m Non‑Dilutive Belgian Funding VolitionRx secured €2m in non-dilutive funding from Belgian agencies on Mar 31, 2026, a development that could extend runway and validate local clinical efforts.

VolitionRx Secures €2m Non‑Dilutive Belgian Funding: VolitionRx secured €2m in non-dilutive funding from Belgian agencies on Mar 31, 2026, a development that could extend runway and validate local clinical efforts. 👈 Read full analysis #VolitionRx #Funding #Belgium #Diagnostics #Healthcare

Thiard News@F4F

@newsen.bsky.social

5 days ago

VolitionRx Receives €2.0 Million Non-Dilutive Funding from Belgian Government Agencies VolitionRx Limited has secured €2.0 million in non-dilutive funding to enhance its epigenetic research and product development efforts in Belgium.

VolitionRx Receives €2.0 Million Non-Dilutive Funding from Belgian Government Agencies #Belgium #funding #VolitionRx #Namur

Thiard News@F4F

@newsen.bsky.social

6 days ago

Nu.Q® Study by VolitionRx Highlights Elevated Biomarkers in Trauma Patients VolitionRx Limited's recent study published in Shock Journal indicates elevated Nu.Q® levels in trauma patients, unveiling potential biomarkers for improved patient care.

Nu.Q® Study by VolitionRx Highlights Elevated Biomarkers in Trauma Patients #United_States #Rochester #VolitionRx #Nu.Q® #Mayo_Clinic

Thiard News@F4F

@newsen.bsky.social

1 week ago

VolitionRx Unveils Groundbreaking Research on Lung Cancer Risk Stratification at ELCC Discover VolitionRx's latest abstract at the European Lung Cancer Conference, showcasing groundbreaking findings in lung cancer risk management.

VolitionRx Unveils Groundbreaking Research on Lung Cancer Risk Stratification at ELCC #USA #Henderson #VolitionRx #H3K27Me3 #nucleosome

Thiard News@F4F

@newsen.bsky.social

1 week ago

Volition's New Technology Detects Over 95% of Early-Stage Cancers Using Liquid Biopsy VolitionRx Limited has announced impressive results showing its Capture-Seq™ technology is capable of detecting over 95% of early-stage cancers, paving the way for earlier diagnoses.

Volition's New Technology Detects Over 95% of Early-Stage Cancers Using Liquid Biopsy #USA #Henderson #VolitionRx #Capture-Seq #Early-Cancer-Detection

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

VolitionRx Achieves Major Breakthrough in Liquid Biopsy with Over 99% Cancer DNA Purity VolitionRx Limited makes significant strides in liquid biopsy technology, achieving over 99% purity in isolating cancer-derived DNA, paving the way for early detection.

VolitionRx Achieves Major Breakthrough in Liquid Biopsy with Over 99% Cancer DNA Purity #United_States #Liquid_Biopsy #cancer_detection #VolitionRx #Henderson,_Nevada

Thiard News@F4F

@newsen.bsky.social

4 weeks ago

Volition and Fujifilm Launch Revolutionary Automated Nu.Q® Vet Cancer Test in Japan VolitionRx, in collaboration with Fujifilm, unveils the first automated Nu.Q® Vet Cancer Test, streamlining canine cancer detection in Japan's veterinary landscape.

Volition and Fujifilm Launch Revolutionary Automated Nu.Q® Vet Cancer Test in Japan #Japan #Henderson #VolitionRx #Nu.Q®_Vet_Cancer_Test #Fujifilm_Vet_Systems

Thiard News@F4F

@newsen.bsky.social

1 month ago

VolitionRx Reports Remarkable Progress in Cancer Detection and Veterinary Diagnostics VolitionRx Limited showcases impressive advancements in cancer detection and veterinary diagnostics, emphasizing innovative methods and significant partnerships.

VolitionRx Reports Remarkable Progress in Cancer Detection and Veterinary Diagnostics #USA #cancer_detection #VolitionRx #Henderson,_Nevada #VNRX

Thiard News@F4F

@newsen.bsky.social

1 month ago

VolitionRx Expands Reach in Japan with New Distributor for Nu.Q® Discover Assays VolitionRx has announced a partnership with Medical & Biological Laboratories Co., Ltd as a distributor for Nu.Q® Discover in Japan, enhancing disease research.

VolitionRx Expands Reach in Japan with New Distributor for Nu.Q® Discover Assays #Japan #Henderson #VolitionRx #Nu.Q #Medical_&_Biological_Laboratories

Thiard News@F4F

@newsen.bsky.social

2 months ago

VolitionRx Prepares for Reimbursement Submission of Nu.Q® Cancer Assays in France VolitionRx Limited is working towards a reimbursement submission for its Nu.Q® Cancer assays in France, supported by Hospices Civils de Lyon.

VolitionRx Prepares for Reimbursement Submission of Nu.Q® Cancer Assays in France #VolitionRx #Nu.Q®_Cancer #Hospices_Civils_de_Lyon

Thiard News@F4F

@newsen.bsky.social

2 months ago

VolitionRx Launches Clinical Study on Nu.Q® NETs for Chronic Disease Management VolitionRx Limited announces a pivotal study demonstrating the efficacy of its Nu.Q® NETs assay for managing Hidradenitis Suppurativa, a chronic skin condition affecting many worldwide.

VolitionRx Launches Clinical Study on Nu.Q® NETs for Chronic Disease Management #United_States #Henderson #VolitionRx #Hidradenitis_Suppurativa #Nu.Q_NETs

Thiard News@F4F

@newsen.bsky.social

2 months ago

Volition Expands Access to Nu.Q® Vet Cancer Test Across America and Asia VolitionRx Limited has taken significant steps to enhance the availability of its Nu.Q® Vet Cancer Test in the U.S. and Asia, marking an important milestone in canine cancer detection.

Volition Expands Access to Nu.Q® Vet Cancer Test Across America and Asia #USA #Henderson #VolitionRx #Nu.Q® #Canine_Cancer

Thiard News@F4F

@newsen.bsky.social

2 months ago

VolitionRx Completes $2 Million Funding Round With Significant Investor Partnership VolitionRx Limited has successfully secured $2 million in funding through an amended securities purchase agreement with Lind Global Asset Management.

VolitionRx Completes $2 Million Funding Round With Significant Investor Partnership #United_States #Henderson #VolitionRx #epigenetics #Lind_Global_Asset_Management

Thiard News@F4F

@newsen.bsky.social

2 months ago

VolitionRx Unveils Innovative Nu.Q Vet Cancer Test for Cats with Breakthrough Clinical Results VolitionRx Limited announces promising clinical study results for its Nu.Q® Vet Feline assay, which detects feline lymphoma with high accuracy.

VolitionRx Unveils Innovative Nu.Q Vet Cancer Test for Cats with Breakthrough Clinical Results #United_States #Henderson #VolitionRx #Nu.Q_Vet_Test #Feline_Cancer

Thiard News@F4F

@newsen.bsky.social

3 months ago

VolitionRx Limited Releases In-Depth Business Review for 2025 Progress VolitionRx Limited details significant milestones achieved in 2025, focused on epigenetics and diagnostic innovations to combat cancer and sepsis, promising transformative advancements.

VolitionRx Limited Releases In-Depth Business Review for 2025 Progress #USA #VolitionRx #epigenetics #Henderson,_NV #Nu.Q_Cancer

Thiard News@F4F

@newsen.bsky.social

3 months ago

VolitionRx Unveils Groundbreaking Technique for Liquid Biopsy with 180-Fold Enrichment VolitionRx has introduced a revolutionary method to enhance liquid biopsy, achieving astounding 180-fold enrichment that could change cancer detection forever.

VolitionRx Unveils Groundbreaking Technique for Liquid Biopsy with 180-Fold Enrichment #United_States #Liquid_Biopsy #Henderson #VolitionRx #Capture-Seq

Thiard News@F4F

@newsen.bsky.social

3 months ago

VolitionRx Showcases Groundbreaking Research at NA Conference on Lung Cancer VolitionRx Limited presents two significant abstracts at the North America Conference on Lung Cancer, highlighting advancements in cancer diagnostics via Nu.Q assays.

VolitionRx Showcases Groundbreaking Research at NA Conference on Lung Cancer #United_States #Chicago #VolitionRx #Lung_Cancer #Nu.Q_Cancer

Thiard News@F4F

@newsen.bsky.social

4 months ago

VolitionRx's New Biomarker for Early Sepsis Detection Takes Center Stage in France VolitionRx has announced its innovative Nu.Q® NETs H3.1 assay's inclusion in France's DETECSEPS project, enhancing early sepsis detection.

VolitionRx's New Biomarker for Early Sepsis Detection Takes Center Stage in France #Paris #France #VolitionRx #Nu.Q® #sepsis

Thiard News@F4F

@newsen.bsky.social

4 months ago

VolitionRx's Nu.Q® Cancer Assays Take a Major Step Towards Clinical Use VolitionRx announced its first sale of Nu.Q® Cancer assays to a leading European cancer center, marking a significant development for cancer diagnostics.

VolitionRx's Nu.Q® Cancer Assays Take a Major Step Towards Clinical Use #USA #Henderson #VolitionRx #Nu.Q #Cancer

Thiard News@F4F

@newsen.bsky.social

4 months ago

VolitionRx Reports Third Quarter 2025 Financial Results and Business Developments VolitionRx Limited announces its financial results and business updates for Q3 2025, highlighting significant partnerships and revenue growth.

VolitionRx Reports Third Quarter 2025 Financial Results and Business Developments #USA #Henderson #VolitionRx #epigenetics #Nu.Q

Thiard News@F4F

@newsen.bsky.social

5 months ago

VolitionRx Supports Crisis Response Canines with Nu.Q® Vet Cancer Tests Donation VolitionRx has made a significant contribution by donating Nu.Q® Vet Cancer Tests to support HOPE Animal-Assisted Crisis Response Dogs, enhancing the health of these vital animals.

VolitionRx Supports Crisis Response Canines with Nu.Q® Vet Cancer Tests Donation #USA #Virginia_Beach #VolitionRx #Hope #cancer_tests

Thiard News@F4F

@newsen.bsky.social

5 months ago

VolitionRx Limited Secures $6 Million in Public Offering to Advance Epigenetic Research and Product Development VolitionRx Limited has announced a $6 million underwritten public offering aimed at fueling continued epigenetic research and product commercialization efforts.

VolitionRx Limited Secures $6 Million in Public Offering to Advance Epigenetic Research and Product Development #USA #stock_offering #Henderson #VolitionRx #epigenetics

Thiard News@F4F

@newsen.bsky.social

6 months ago

VolitionRx Sponsors Innovative Webinar on Epigenetic Modifications and Drug Discovery Join VolitionRx's upcoming webinar on October 8th, focusing on epigenetic modifications for drug discovery. Expert insights and advanced assays will be shared.

VolitionRx Sponsors Innovative Webinar on Epigenetic Modifications and Drug Discovery #United_States #Henderson #VolitionRx #epigenetics #Nu.Q_Discover

Thiard News@F4F

@newsen.bsky.social

6 months ago

VolitionRx Collaborates with Hologic to Enhance Epigenetic Services and Solutions VolitionRx and Hologic have entered into a co-marketing agreement aimed at enhancing the accessibility of innovative epigenetic profiling services to drug developers and researchers worldwide.

VolitionRx Collaborates with Hologic to Enhance Epigenetic Services and Solutions #United_States #VolitionRx #Henderson,_Nevada #Hologic #Nu.Q_Discover

Thiard News@F4F

@newsen.bsky.social

6 months ago

VolitionRx Partners with Werfen for Innovative APS Diagnostics VolitionRx has signed a pivotal licensing agreement with Werfen to advance diagnostic options for Antiphospholipid Syndrome, enhancing patient management strategies.

VolitionRx Partners with Werfen for Innovative APS Diagnostics #USA #Werfen #Henderson #VolitionRx #Antiphospholipid_Syndrome

Thiard News@F4F

@newsen.bsky.social

8 months ago

VolitionRx Advances with $1.2 Million Direct Offering for Growth in Epigenetics VolitionRx Limited recently announced a $1.2 million direct offering, aimed at funding its innovative epigenetics research and product development efforts.

VolitionRx Advances with $1.2 Million Direct Offering for Growth in Epigenetics #USA #stock_offering #Henderson #VolitionRx #epigenetics

Thiard News@F4F

@newsen.bsky.social

8 months ago

VolitionRx's Nu.Q® Discover: A Leap in Epigenetic Innovation and Global Reach VolitionRx's Nu.Q® Discover program shows promising advancements in epigenetics, targeting a $200M market, with strong growth and collaboration prospects ahead.

VolitionRx's Nu.Q® Discover: A Leap in Epigenetic Innovation and Global Reach #United_States #Henderson #VolitionRx #epigenetics #Nu.Q®_Discover

Thiard News@F4F

@newsen.bsky.social

8 months ago

VolitionRx Unveils Innovative Lateral Flow Test for Nucleosome Quantification at Point-of-Care Settings VolitionRx Limited presents a significant breakthrough: a lateral flow test capable of rapid nucleosome quantification in whole blood, enhancing patient outcomes in critical care.

VolitionRx Unveils Innovative Lateral Flow Test for Nucleosome Quantification at Point-of-Care Settings #United_States #Henderson #VolitionRx #nucleosome_test #SUMMIT_program